Nordic Nanovector

Nordic Nanovector ASA announced 6th of June the signing of an agreement to acquire Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, in an all-share transaction. The agreed post-transaction share exchange ratio is 50%/50% assuming that all shares in Thor Medical are acquired.
 
Thor Medical, based in Oslo, Norway, has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. Thor Medical will supply alpha emitters to radiopharmaceutical companies for the development of innovative, tumour-targeted cancer therapies.
 
Carnegie Investment Bank congratulates all parties involved with the signing of the agreement and is proud to act as Financial Advisor to Nordic Nanovector ASA in the acquisition.